Intraocular pressure and endothelium cell counts after cataract surgery with chitosan and sodium hyaluronate (Healon GV): 3-Year follow-up results of a randomised clinical trial
Introduction The purpose of this study was to evaluate the long-term effects of chitosan 0.1% and sodium hyaluronate 1.4% (Healon GV®; Advanced Medical Optics, Santa Ana, CA, USA) on intraocular pressure (IOP) and endothelial cell loss. Methods This randomised study comprised 140 eyes of 140 patient...
Saved in:
Published in | Advances in therapy Vol. 25; no. 5; pp. 422 - 429 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Heidelberg
Springer Healthcare Communications
01.05.2008
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Introduction
The purpose of this study was to evaluate the long-term effects of chitosan 0.1% and sodium hyaluronate 1.4% (Healon GV®; Advanced Medical Optics, Santa Ana, CA, USA) on intraocular pressure (IOP) and endothelial cell loss.
Methods
This randomised study comprised 140 eyes of 140 patients with age-related cataracts undergoing phacoemulsification followed by posterior chamber intraocular lens (IOL) implantation; 70 received chitosan 0.1%, and 70 received sodium hyaluronate 1.4%. The IOP was measured with standard Goldman applanation tonometry pre-operatively and 1 day, 1 week, 1 month, 3 months, 1 year and 3 years postoperatively. Endothelial cell counts were performed pre-operatively and 1 week, 1 month, 3 months, 1 year and 3 years postoperatively using a Pro/Koester WFSCM contact endothelial microscope.
Results
There were no significant differences found in postoperative IOP levels among the chitosan and sodium hyaluronate groups (
P
>0.05). No significant differences were found in postoperative mean endothelial cell counts at all time points between the chitosan and sodium hyaluronate groups (
P
>0.05).
Conclusion
Chitosan has the same effects as sodium hyaluronate on IOP and endothelium cells counts after cataract surgery and IOL implantation, and therefore may be an alternative ophthalmic viscoelastic device. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-News-1 ObjectType-Feature-3 content type line 23 |
ISSN: | 0741-238X 1865-8652 |
DOI: | 10.1007/s12325-008-0059-1 |